GAC - Great write up to the last paragraph. There is quite a difference between a company that has a product that reduces potassium levels for CKD patients and one that hopefully has a positive effect on Diabetic, CKD, Cardio and cognitively impaired patients. The potential market for apabetalone is massive in comparison to the limited market for Patiromer. That is kind of like comparing apples, oranges, grapes and chocolate chip cookies.

tada